XW 017
Alternative Names: XW-017Latest Information Update: 13 Jun 2022
At a glance
- Originator Sciwind Biosciences
- Class Antihypercalcaemics; Hepatoprotectants; Obesity therapies; Recombinant proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 08 Jun 2022 Sciwind Biosciences plans a clinical trial in the first half of 2023
- 21 Jan 2022 Preclinical trials in Non-alcoholic steatohepatitis in China (unspecified route) (Sciwind Biosciences pipeline, January 2022)
- 21 Jan 2022 Preclinical trials in Obesity in China (unspecified route) (Sciwind Biosciences pipeline, January 2022)